<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01099137</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH_ENDO3</org_study_id>
    <nct_id>NCT01099137</nct_id>
  </id_info>
  <brief_title>Effect of Vildagliptin in Type 2 Diabetes Treated With Sulphonylurea and Metformin</brief_title>
  <official_title>The Study About Glucose Lowering Effect of Vildagliptin in Type 2 Diabetes Patients Who Are Uncontrolled With Metformin and a Sulphonylurea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dual combination therapy with metformin and sulphonylurea is the most commonly used
      combination regimen to treat patients with type 2 diabetes. But, treatment with the dual
      combination therapy is often unsuccessful at achieving glycaemic control in patients with
      type 2 diabetes. In this setting, use of insulin is often the next therapeutic step.

      Recently, dipeptidyl peptidase (DPP)-IV inhibitor is increasingly being used in clinical
      practice. It is well established that DPP-IV inhibitor improve glycemic control in patients
      with type 2 diabetes.

      But, there have been few studies about the glucose lowering effect of DPP-IV inhibitors
      (vildagliptin) in Type 2 diabetes patients on the dual combination therapy with a
      sulfonylurea agent and metformin.The researchers hypothesized that DPP-IV inhibitor as add-on
      therapy to combination of a sulfonylurea agent and metformin have favorable glucose lowering
      effect in type 2 diabetic patients. The researchers plan to investigate the change in HbA1C
      and fasting glucose of 24 weeks treatment with vildagliptin (DPP-IV inhibitor) in combination
      with a sulfonylurea agent and metformin in type 2 diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of HbA1c</measure>
    <time_frame>24weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose (FPG)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Plasma Glucose (PPG)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c &lt; 7.0% without hypoglycemia</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">344</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Vildagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vildagliptin will be added to uncontrolled diabetic patients with sulphonylurea and metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulphonylurea dose-up</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sulphonylurea dose will be increased to uncontrolled diabetic patients with sulphonylurea and metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin</intervention_name>
    <description>Vildagliptin 50mg twice a day, orally, for 24 weeks</description>
    <arm_group_label>Vildagliptin</arm_group_label>
    <other_name>Galvus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulphonylurea dose-up</intervention_name>
    <description>glimepiride dose will be increased by 50% to uncontrolled diabetic patients with glimepiride and metformin</description>
    <arm_group_label>Sulphonylurea dose-up</arm_group_label>
    <other_name>Amaryl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  HbA1c ≥ 7%

          -  Age ≥ 18

        Exclusion Criteria:

          -  Contraindication to Vildagliptin

          -  Pregnant or breast feeding women

          -  Type 1 diabetes, gestational diabetes, or diabetes with secondary cause

          -  Chronic hepatitis B or C (except healthy carrier of HBV)

          -  Liver disease (AST/ALT &gt; 3-fold the upper limit of normal)

          -  Renal failure (Cr &gt; 2.0)

          -  Cancer within 5 years

          -  Not appropriate for oral antidiabetic agent

          -  Medication which affect glycemic control

          -  Disease which affect efficacy and safety of drugs

          -  Other clinical trial within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soo Lim, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2010</study_first_submitted>
  <study_first_submitted_qc>April 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2010</study_first_posted>
  <last_update_submitted>May 26, 2014</last_update_submitted>
  <last_update_submitted_qc>May 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Soo Lim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Vildagliptin</keyword>
  <keyword>insulin</keyword>
  <keyword>C-peptide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vildagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

